Johnson & Johnson has inked a collaboration with the Singapore Economic Development Board to boost life sciences innovation in the region, touting the pact as the “first of its kind.”

强生公司已与新加坡经济发展委员会（Singapore Economic Development Board）签署合作协议，以推动该地区的生命科学创新，并将该协议吹捧为“同类协议中的首例”

Under the new partnership, Johnson & Johnson’s incubator—dubbed JLABS—will help early-stage companies in Singapore develop their discoveries into medicines, medical technologies and healthcare solutions. JLABS will also work with local partners regarding venture and talent offerings to foster employment and commercialization opportunities..

根据新的合作关系，强生公司的孵化器JLABS将帮助新加坡的早期公司将其发现发展为药物、医疗技术和医疗保健解决方案。JLABS还将与当地合作伙伴合作，提供创业和人才，以促进就业和商业化机会。。

The pact demonstrates J&J’s commitment to advancing science and technology in the Asia Pacific region to address global needs, the Big Pharma’s Chief External Innovation and Medical Officer William Hait, M.D., Ph.D., said in the Sept. 26 release.

该协议表明强生致力于推进亚太地区的科学技术，以满足全球需求，这家大型制药公司的首席外部创新和医疗官威廉·海特（WilliamHait）医学博士在9月26日的新闻稿中表示。

JLABs and the country’s Economic Development Board are set to host a symposium in Singapore before the year ends and share “subsequent announcements” that have emerged from the new collaboration.

JLABs和新加坡经济发展委员会将于年底前在新加坡主办一次研讨会，并分享新合作产生的“后续公告”。

The deal comes as the city-state continues work to become a biotech hub—efforts that launched way back in 2000 when the government made biomedical research the “fourth pillar” of the economy. The billions of dollars pumped into the life sciences sector over the next 20 years have resulted in a few notable success stories, including Chugai’s decision to set up a research institute and GSK’s antibiotic and vaccine manufacturing plants..

该协议达成之际，这个城市国家正继续努力成为生物技术中心，这项努力早在2000年就开始了，当时政府将生物医学研究作为经济的“第四支柱”。未来20年向生命科学领域注入的数十亿美元带来了一些值得注意的成功案例，包括Chugai决定成立一家研究所以及GSK的抗生素和疫苗制造厂。。

Singapore itself isn’t a huge commercial market—or at least not a prime destination for launching a drug. But Singapore as a biopharma manufacturing hub makes sense because of the large market surrounding it, Stephen Sunderland, head of L.E.K.’s Southeast Asia healthcare and life science practice based in Singapore, told Fierce last month..

新加坡本身并不是一个巨大的商业市场，或者至少不是推出药物的主要目的地。但L.E.K.驻新加坡东南亚医疗保健和生命科学业务负责人斯蒂芬·桑德兰（StephenSunderland）上个月告诉《激烈》杂志，新加坡作为生物制药制造中心是有道理的，因为它周围有巨大的市场。。